Limits...
IDH mutations: genotype-phenotype correlation and prognostic impact.

Wang XW, Ciccarino P, Rossetto M, Boisselier B, Marie Y, Desestret V, Gleize V, Mokhtari K, Sanson M, Labussière M - Biomed Res Int (2014)

Bottom Line: We found that the distribution of IDH1(R132H) , IDH1(nonR132H) , and IDH2 mutations differed between astrocytic, mixed, and oligodendroglial tumors, with an overrepresentation of IDH2 mutations in oligodendroglial phenotype and an overrepresentation of IDH1(nonR132H) in astrocytic tumors.We confirmed that IDH mutation with a hazard ratio = 0.358 is an independent prognostic factor of good outcome.These data refine current knowledge on IDH mutation prognostic impact and genotype-phenotype associations.

View Article: PubMed Central - PubMed

Affiliation: Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière (CRICM) UMR-S975, 75013 Paris, France ; INSERM U 975, 75013 Paris, France ; CNRS, UMR 7225, 75013 Paris, France.

ABSTRACT
IDH1/2 mutation is the most frequent genomic alteration found in gliomas, affecting 40% of these tumors and is one of the earliest alterations occurring in gliomagenesis. We investigated a series of 1305 gliomas and showed that IDH mutation is almost constant in 1p19q codeleted tumors. We found that the distribution of IDH1(R132H) , IDH1(nonR132H) , and IDH2 mutations differed between astrocytic, mixed, and oligodendroglial tumors, with an overrepresentation of IDH2 mutations in oligodendroglial phenotype and an overrepresentation of IDH1(nonR132H) in astrocytic tumors. We stratified grade II and grade III gliomas according to the codeletion of 1p19q and IDH mutation to define three distinct prognostic subgroups: 1p19q and IDH mutated, IDH mutated--which contains mostly TP53 mutated tumors, and none of these alterations. We confirmed that IDH mutation with a hazard ratio = 0.358 is an independent prognostic factor of good outcome. These data refine current knowledge on IDH mutation prognostic impact and genotype-phenotype associations.

Show MeSH

Related in: MedlinePlus

Prognostic impact of IDH status on overall survival (a) and progression free survival (b) in grade II to IV gliomas.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4022066&req=5

fig1: Prognostic impact of IDH status on overall survival (a) and progression free survival (b) in grade II to IV gliomas.

Mentions: We investigated the prognostic impact of IDH status in grade II, grade III, and grade IV gliomas. For each grade, IDH mutated patients have significantly longer overall survival and progression free survival than IDH normal patients (Figure 1 and Table 2).


IDH mutations: genotype-phenotype correlation and prognostic impact.

Wang XW, Ciccarino P, Rossetto M, Boisselier B, Marie Y, Desestret V, Gleize V, Mokhtari K, Sanson M, Labussière M - Biomed Res Int (2014)

Prognostic impact of IDH status on overall survival (a) and progression free survival (b) in grade II to IV gliomas.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4022066&req=5

fig1: Prognostic impact of IDH status on overall survival (a) and progression free survival (b) in grade II to IV gliomas.
Mentions: We investigated the prognostic impact of IDH status in grade II, grade III, and grade IV gliomas. For each grade, IDH mutated patients have significantly longer overall survival and progression free survival than IDH normal patients (Figure 1 and Table 2).

Bottom Line: We found that the distribution of IDH1(R132H) , IDH1(nonR132H) , and IDH2 mutations differed between astrocytic, mixed, and oligodendroglial tumors, with an overrepresentation of IDH2 mutations in oligodendroglial phenotype and an overrepresentation of IDH1(nonR132H) in astrocytic tumors.We confirmed that IDH mutation with a hazard ratio = 0.358 is an independent prognostic factor of good outcome.These data refine current knowledge on IDH mutation prognostic impact and genotype-phenotype associations.

View Article: PubMed Central - PubMed

Affiliation: Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière (CRICM) UMR-S975, 75013 Paris, France ; INSERM U 975, 75013 Paris, France ; CNRS, UMR 7225, 75013 Paris, France.

ABSTRACT
IDH1/2 mutation is the most frequent genomic alteration found in gliomas, affecting 40% of these tumors and is one of the earliest alterations occurring in gliomagenesis. We investigated a series of 1305 gliomas and showed that IDH mutation is almost constant in 1p19q codeleted tumors. We found that the distribution of IDH1(R132H) , IDH1(nonR132H) , and IDH2 mutations differed between astrocytic, mixed, and oligodendroglial tumors, with an overrepresentation of IDH2 mutations in oligodendroglial phenotype and an overrepresentation of IDH1(nonR132H) in astrocytic tumors. We stratified grade II and grade III gliomas according to the codeletion of 1p19q and IDH mutation to define three distinct prognostic subgroups: 1p19q and IDH mutated, IDH mutated--which contains mostly TP53 mutated tumors, and none of these alterations. We confirmed that IDH mutation with a hazard ratio = 0.358 is an independent prognostic factor of good outcome. These data refine current knowledge on IDH mutation prognostic impact and genotype-phenotype associations.

Show MeSH
Related in: MedlinePlus